ERBB3 and neoplasm: NRG1 can bind HER3 on tumor cells and promote HER2/HER3 signaling, engaging survival pathways such as PI3K–AKT under AR inhibition and thereby sustaining survival and fostering resistance to antiandrogen therapy [126].